NASDAQ:EYEN - Eyenovia Stock Price, Forecast & News

Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."

Eyenovia Inc (NASDAQ:EYEN) issued its earnings results on Wednesday, November, 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.05. View Eyenovia's Earnings History.

Eyenovia is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Eyenovia.

3 Wall Street analysts have issued 12-month price targets for Eyenovia's stock. Their forecasts range from $9.00 to $10.00. On average, they anticipate Eyenovia's share price to reach $9.50 in the next year. This suggests a possible upside of 143.6% from the stock's current price. View Analyst Price Targets for Eyenovia.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyenovia.

News coverage about EYEN stock has trended very negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eyenovia earned a daily sentiment score of -4.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the next several days. View News Stories for Eyenovia.

Eyenovia saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 313,100 shares, an increase of 21.6% from the January 30th total of 257,500 shares. Based on an average daily volume of 83,900 shares, the days-to-cover ratio is presently 3.7 days. Approximately 3.3% of the company's shares are short sold. View Eyenovia's Current Options Chain.

Some companies that are related to Eyenovia include Kamada (KMDA), AMAG Pharmaceuticals (AMAG), Gemphire Therapeutics (GEMP), OptiNose (OPTN), Concert Pharmaceuticals (CNCE), Seres Therapeutics (MCRB), Syros Pharmaceuticals (SYRS), Aduro BioTech (ADRO), BIOFRONTERA AG/ADR (BFRA), Kalvista Pharmaceuticals (KALV), VBI Vaccines (VBIV), Bicycle Therapeutics (BCYC), Protagonist Therapeutics (PTGX), IVERIC bio (ISEE) and Ocular Therapeutix (OCUL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyenovia investors own include Zynerba Pharmaceuticals (ZYNE), Axsome Therapeutics (AXSM), ImmunoGen (IMGN), Nabriva Therapeutics (NBRV), Fate Therapeutics (FATE), Iovance Biotherapeutics (IOVA), Ovid Therapeutics (OVID), AbbVie (ABBV), Aeglea Bio Therapeutics (AGLE) and Allena Pharmaceuticals (ALNA).

(EYEN) raised $30 million in an initial public offering (IPO) on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ acted as the underwriters for the IPO.

Eyenovia's stock is owned by many different of retail and institutional investors. Top institutional shareholders include National Asset Management Inc. (0.07%) and Virtu Financial LLC (0.06%). Company insiders that own Eyenovia stock include Charles E Iv Mather, Curt H Labelle, John P Gandolfo, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev. View Institutional Ownership Trends for Eyenovia.

EYEN stock was purchased by a variety of institutional investors in the last quarter, including National Asset Management Inc. and Virtu Financial LLC. Company insiders that have bought Eyenovia stock in the last two years include Charles E Iv Mather, Curt H Labelle, John P Gandolfo, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev. View Insider Buying and Selling for Eyenovia.

Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EYEN stock can currently be purchased for approximately $3.90.

Eyenovia has a market capitalization of $64.12 million. The company earns $-17,250,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. View Additional Information About Eyenovia.

The official website for Eyenovia is http://www.eyenoviabio.com/.

Eyenovia's mailing address is 295 Madison Avenue Suite 2400, New York NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected]